Αποτελέσματα Αναζήτησης
18 Μαΐ 2023 · Saturn Study. @Saturn_Study. Clinical trial aiming to understand if Methylphenidate or Guanfacine medication is better for treating young people with ADHD and tics. Funded by. @NIHRresearch. Researcher institutemh.org.uk/research/proje… Joined May 2023. 34 Following. 6 Followers. Replies. Media. Likes. @Saturn_Study hasn’t Tweeted.
The Sequential Tarceva in Unresectable NSCLC (SATURN) trial was designed to investigate the effectiveness of maintenance erlotinib treatment until the time of progression, with the goal of prolonging overall survival and delaying disease progression .
15 Οκτ 2010 · In the placebo-controlled phase III SATURN study, maintenance erlotinib after first-line chemotherapy demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS) in the overall study population of patients with advanced non-small-cell lung cancer (NSCLC).
13 Ιουλ 2009 · Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) who...
7 Νοε 2008 · SATURN is a placebo-controlled, randomized, double-blind, Phase III study conducted by Roche that enrolled 889 patients with advanced NSCLC at approximately 160 sites worldwide.
3 Οκτ 2011 · The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable NSCLC (SATURN; BO18192) study evaluated maintenance erlotinib in patients with nonprogressive disease following first-line platinum-doublet chemotherapy.
The global phase III SequentiAl Tarceva in UnResectable NSCLC (SATURN) study evaluated the efficacy and safety of the epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib as maintenance treatment in NSCLC patients without progression after first-line chemotherapy.
